See the DrugPatentWatch profile for cosentyx

Based on the available information, there is no explicit statement or data regarding the administration of live vaccines during Cosentyx (secukinumab) treatment. Cosentyx is a biologic medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2].

The Centers for Disease Control and Prevention (CDC) generally recommends against administering live vaccines to immunocompromised individuals, as their immune system may not mount an adequate response, or there may be a risk of infection [3]. Biologic medications like Cosentyx work by affecting specific parts of the immune system, which could potentially increase the risk of infection or reduce the effectiveness of live vaccines [3].

However, the specific interaction between Cosentyx and live vaccines is not addressed in the provided sources. It is essential to consult a healthcare professional for personalized advice, as they can evaluate the potential risks and benefits based on the individual's medical history and current health status [1][2][3].

In summary, the available information does not provide a clear answer regarding the administration of live vaccines during Cosentyx treatment. It is recommended to consult a healthcare professional for personalized advice.

Sources:

1. [COSENTYX](https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX)
2. [Secukinumab for the treatment of plaque psoriasis: a cost-effectiveness analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767096/)
3. [General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html)